News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City, highlighting evenamide's potential in treating treatment-resistant schizophrenia. Leading experts present clinical data and benefits of evenamide -
-
-
-